|
Volumn 21, Issue 9, 2006, Pages 1003-1004
|
Why disclosure?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIBIOTIC AGENT;
CLOZAPINE;
DULOXETINE;
IMMUNOSUPPRESSIVE AGENT;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY TGN 1412;
TROVAFLOXACIN;
UNCLASSIFIED DRUG;
CAUSE OF DEATH;
CHILDHOOD MORTALITY;
CLINICAL RESEARCH;
CLINICAL TRIAL;
CONFLICT OF INTEREST;
DRUG INDUSTRY;
EDITORIAL;
EPIDEMIC;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
MEDICAL ETHICS;
MEDICAL RESEARCH;
MENINGITIS;
MULTIPLE ORGAN FAILURE;
MYOCARDITIS;
PHASE 1 CLINICAL TRIAL;
RESEARCH ETHICS;
RESEARCH SUBJECT;
SUICIDE;
TUBERCULOSIS;
ADOLESCENT;
ADULT;
CHILD;
CLINICAL TRIALS;
CONFLICT OF INTEREST;
DISCLOSURE;
ETHICS, BUSINESS;
HUMANS;
|
EID: 33746557386
PISSN: 08848734
EISSN: 15251497
Source Type: Journal
DOI: 10.1007/BF02743153 Document Type: Editorial |
Times cited : (7)
|
References (11)
|